Audit 342804

FY End
2024-07-31
Total Expended
$1.65M
Findings
0
Programs
1
Organization: Cure Rare Disease Inc. (CT)
Year: 2024 Accepted: 2025-02-18
Auditor: Leaf & Cole LLP

Organization Exclusion Status:

Checking exclusion status...

Findings

No findings recorded

Programs

ALN Program Spent Major Findings
93.493 Congressional Directives $1.65M Yes 0

Contacts

Name Title Type
FV1JMDQ2L1R6 Rich Horgan Auditee
3802251879 Jenny Kikuno Auditor
No contacts on file

Notes to SEFA

Title: Basis of Presentation Accounting Policies: Expenditures reported on the Schedule are reported on the accrual basis of accounting. Such expenditures are recognized following the cost principles contained in the Uniform Guidance, wherein certain types of expenditures are not allowable or are limited as to reimbursement. De Minimis Rate Used: Y Rate Explanation: The auditee did use the 10-percent de minimis indirect cost rate as allowed under Uniform Guidance. The accompanying schedule of expenditures of federal awards (the Schedule) includes the federal award activity of Cure Rare Disease under programs of the federal government for the year ended July 31, 2024. The information in this Schedule is presented in accordance with the requirements of Title 2 U.S. Code of Federal Regulations Part 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards (Uniform Guidance). Because the Schedule presents only a selected portion of the operations of Cure Rare Disease, it is not intended to and does not present the financial position, changes in net assets, or cash flows of Cure Rare Disease.